Contact

Category: Sciences

  • US FDA puts Kezar Life Sciences’ lupus treatment trial on hold after patient deaths By Reuters

    •

    Investor Empires

    (Reuters) – The US Food and Drug Administration imposed a clinical suspension on the drug Kezar Life Sciences (NASDAQ:)’ trial of an experimental drug for lupus, the company said Friday. The FDA’s decision comes after the company said it had temporarily halted a mid-stage trial of the drug, zetomipzomib, to…

  • Cassava Sciences stock tumbles as CEO Remi Barbier resigns (NASDAQ:SAVA)

    •

    Investor Empires

    Cassava ScienceNASDAQ:SAVAGeneral Electric Automotive Co. announced changes to its executive leadership on Wednesday, with Richard Barry taking over as the company’s chief executive officer and executive chairman of the board. The neuroscience-focused pharmaceutical company is researching a new drug. Permanent CEO to replace Remi Barbier who resigned from the company…

  • Gilead Sciences stock upgraded by Raymond James on strong growth outlook for new drugs By Investing.com

    •

    Investor Empires

    On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered by promising data from the PURPOSE-1 study of lenacapavir, a long-acting HIV pre-exposure prophylaxis…